tiprankstipranks
Trending News
More News >
Beamtree Holdings Ltd (AU:BMT)
ASX:BMT
Australian Market
Advertisement

Beamtree Holdings Ltd (BMT) AI Stock Analysis

Compare
10 Followers

Top Page

AU

Beamtree Holdings Ltd

(Sydney:BMT)

Rating:55Neutral
Price Target:
AU$0.50
▲(85.19%Upside)
Beamtree Holdings Ltd's score is primarily influenced by its financial performance challenges and valuation difficulties. Despite some technical stability, the lack of profitability and negative P/E ratio weigh heavily on the overall assessment.

Beamtree Holdings Ltd (BMT) vs. iShares MSCI Australia ETF (EWA)

Beamtree Holdings Ltd Business Overview & Revenue Model

Company DescriptionBeamtree Holdings Limited develops and commercializes clinical decision support (CDS) systems to healthcare industry in Australia and internationally. The company offers RippleDown Expert, a CDS system that provides real-time patient monitoring and alerting solutions; RippleDown Auditor, that automates real-time reviews of data, ensuring accuracy across data entry, billing, specimen reception, and flagging suspected errors; and PICQ, a coding quality assessment tool for public and private hospitals, health services, and state health departments that assesses and reports clinically coded data. It also provides RISQ, a measurement, benchmarking, and management tool for hospital-acquired complications; Q Coding Platform, an end-to-end workflow suite for clinical coding, grouping, reporting, and auditing; and Codexpert, a searchable eBook application that offers classification reference information for clinical coding patient records. The company offers advisory and auditing solution, such as desktop analysis, data maturity index, and physical audits. It serves customers through channel partners. The company was formerly known as PKS Holdings Limited and changed its name to Beamtree Holdings Limited in August 2021. Beamtree Holdings Limited was founded in 1996 and is headquartered in Redfern, Australia.
How the Company Makes MoneyBeamtree Holdings Ltd generates revenue primarily through the sale and licensing of its software and analytics solutions to healthcare providers and institutions. The company's key revenue streams include subscription fees for its software-as-a-service (SaaS) solutions, licensing fees for its decision support tools, and professional services fees for implementation and consulting services. Additionally, Beamtree may engage in strategic partnerships with healthcare organizations, technology firms, and government bodies, which can contribute to its earnings through collaborative projects and shared revenue models. The company's focus on innovation and its ability to address critical needs in the healthcare sector are significant factors in its financial performance.

Beamtree Holdings Ltd Financial Statement Overview

Summary
Beamtree Holdings Ltd displays strong revenue growth but faces profitability and cash flow challenges. The company's equity position is strong, yet negative profit margins and operational inefficiencies highlight areas for improvement.
Income Statement
58
Neutral
Beamtree Holdings Ltd has shown significant revenue growth, with a Revenue Growth Rate of 21.21% from 2023 to 2024. However, the company is struggling with profitability, as indicated by negative EBIT and Net Income, leading to a negative Net Profit Margin (-18.5%) for the latest period. Despite improvement in gross profit, the negative EBITDA Margin indicates operational challenges.
Balance Sheet
64
Positive
The company maintains a strong equity position with an Equity Ratio of 79.0%, signaling financial stability. The Debt-to-Equity Ratio is low at 0.04, indicating minimal leverage risk. However, negative returns such as ROE (-10.8%) suggest inefficiencies in utilizing shareholder funds.
Cash Flow
50
Neutral
Operating cash flow has turned negative in the latest period, reflecting potential liquidity concerns. The Free Cash Flow remains negative, but the company has historically managed to improve its cash position. The Operating Cash Flow to Net Income Ratio is not meaningful due to negative net income.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue27.60M22.77M19.09M8.39M4.12M
Gross Profit4.89M2.14M2.34M2.77M2.65M
EBITDA-331.00K-1.24M-2.28M1.02M697.11K
Net Income-5.11M-6.91M-4.45M-383.62K382.90K
Balance Sheet
Total Assets59.65M62.53M63.91M47.05M32.22M
Cash, Cash Equivalents and Short-Term Investments5.04M8.81M6.35M14.12M4.20M
Total Debt1.66M755.00K1.12M799.36K44.27K
Total Liabilities12.52M15.31M15.33M4.96M3.01M
Stockholders Equity47.14M47.22M48.58M42.09M29.22M
Cash Flow
Free Cash Flow-4.51M-1.88M-4.83M-2.64M-26.13K
Operating Cash Flow-492.00K768.00K-2.32M240.65K1.05M
Investing Cash Flow-4.02M-2.65M-5.16M-2.98M-849.49K
Financing Cash Flow749.00K4.34M-286.00K12.65M-128.49K

Beamtree Holdings Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.27
Price Trends
50DMA
0.27
Negative
100DMA
0.25
Positive
200DMA
0.26
Positive
Market Momentum
MACD
>-0.01
Negative
RSI
52.81
Neutral
STOCH
77.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BMT, the sentiment is Positive. The current price of 0.27 is above the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.27, and above the 200-day MA of 0.26, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.81 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BMT.

Beamtree Holdings Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUBMT
55
Neutral
AU$78.45M-11.80%14.56%13.36%
52
Neutral
$7.47B-0.04-63.86%2.34%16.17%0.25%
$56.49M-9.88%
AURHT
60
Neutral
AU$17.93M140.00-3.11%89.13%69.57%
AUMDR
57
Neutral
AU$36.26M110.00-8.34%-5.27%50.29%
AUALC
55
Neutral
AU$141.01M-5.63%-11.96%7.50%
AUPCK
55
Neutral
AU$71.84M-457.46%21.93%10.34%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:BMT
Beamtree Holdings Ltd
0.27
0.05
22.73%
TDMMF
Mach7 Technologies
0.24
-0.12
-33.33%
AU:RHT
Resonance Health Ltd
0.04
-0.01
-20.00%
AU:MDR
MedAdvisor Limited
0.07
-0.47
-87.04%
AU:ALC
Alcidion Group Limited
0.11
0.05
83.33%
AU:PCK
PainChek Ltd
0.04
0.00
0.00%

Beamtree Holdings Ltd Corporate Events

Beamtree Holdings Ltd Issues Shares Under Employee Incentive Plan
Jul 16, 2025

Beamtree Holdings Ltd announced the issuance of 26,082 fully paid ordinary shares under its Employee Incentive Plan. This move is part of salary contribution arrangements aimed at incentivizing employees, potentially enhancing workforce motivation and aligning employee interests with company performance, which could positively impact the company’s operational dynamics and market positioning.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Holdings Announces Cessation of Performance Rights
Jul 11, 2025

Beamtree Holdings Limited has announced the cessation of 3,269,332 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This cessation could impact the company’s capital structure and may have implications for stakeholders regarding the company’s future performance and strategic direction.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Holdings Expands Share Issuance to Strengthen Market Position
Jul 1, 2025

Beamtree Holdings Limited has issued 350,000 fully paid ordinary shares, as announced under Section 708A of the Corporations Act. This move is part of their compliance with relevant provisions of the Corporations Act, and there is no excluded information as per sections 708A(7) and 708A(8). This issuance reflects Beamtree’s ongoing commitment to enhancing its operational capabilities and market presence, potentially impacting stakeholders by reinforcing its financial and strategic positioning within the healthcare technology sector.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Holdings Announces Quotation of New Securities on ASX
Jul 1, 2025

Beamtree Holdings Limited has announced the quotation of 350,000 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from July 1, 2025. This move is part of a previously announced transaction and signifies an important step in the company’s financial strategy, potentially impacting its market presence and providing liquidity for stakeholders.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Holdings Announces Cessation of Performance Rights
Jun 17, 2025

Beamtree Holdings Ltd has announced the cessation of 750,000 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This cessation could impact the company’s capital structure and may influence stakeholders’ perceptions of the company’s ability to meet performance conditions.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Holdings Announces Proposed Securities Issue
Jun 10, 2025

Beamtree Holdings Limited has announced a proposed issue of 350,000 fully paid ordinary securities, scheduled for July 1, 2025. This move is part of a placement or other type of issue, which will be quoted on the ASX, potentially impacting the company’s market presence and offering new opportunities for stakeholders.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Holdings Issues New Shares in Compliance with Corporations Act
Jun 3, 2025

Beamtree Holdings Limited has announced the issuance of 375,000 fully paid ordinary shares without disclosure to investors under Part 6D.2 of the Corporations Act. This move is in compliance with relevant provisions of the Corporations Act, and there is no excluded information as per sections 708A(7) and 708A(8). This announcement reflects Beamtree’s ongoing commitment to adhering to regulatory standards while potentially enhancing its market position and stakeholder value.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Holdings Limited Announces Quotation of New Securities
Jun 3, 2025

Beamtree Holdings Limited has announced the quotation of 375,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code BMT. This move is part of the company’s strategy to enhance its market presence and provide more liquidity to its shareholders, potentially impacting its market positioning positively.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Expands into UK with NHS Confederation Partnership
May 30, 2025

Beamtree Holdings Limited has announced a strategic partnership with the NHS Confederation to expand its presence in the UK healthcare market. This collaboration aims to replicate Beamtree’s successful ANZ membership model within the NHS hospital sector in England, Wales, and Northern Ireland. The partnership will establish a benchmarking collaborative, providing NHS trusts with access to advanced analytics, benchmarking services, and peer-to-peer learning communities. The initial contract is for five years, with an option to extend, and includes a significant investment by Beamtree to establish the platform in the UK. This move is a key part of Beamtree’s growth strategy, offering potential benefits to NHS trusts through enhanced data analytics and operational benchmarking.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Holdings Reports Major Q3 FY25 Progress and Strategic Wins
May 5, 2025

Beamtree Holdings Limited has announced significant progress in its operations for the third quarter of FY25, highlighted by major contract wins and strategic developments. The company has launched the Evolve Collaborative with NHS Confederation in England, renewed a contract in Ireland, and expanded its market presence in Saudi Arabia and the UK. These developments are expected to significantly increase Beamtree’s market share and annual recurring revenue, positioning the company for improved profitability and positive cash generation by the end of FY25.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 12, 2025